|
Volumn 33, Issue 2, 2006, Pages 433-
|
Should anti-tumor necrosis factor-α be the first therapy for rheumatoid vasculitis? [1]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLOPHOSPHAMIDE;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
LEFLUNOMIDE;
METHOTREXATE;
STEROID;
TUMOR NECROSIS FACTOR ALPHA INHIBITOR;
AGED;
CASE REPORT;
ELECTROMYOGRAPHY;
ERYTHROCYTE SEDIMENTATION RATE;
HUMAN;
IMMUNOTHERAPY;
LETTER;
MALE;
MONONEUROPATHY MULTIPLEX;
MOTOR PERFORMANCE;
PRIORITY JOURNAL;
RHEUMATIC DISEASE;
RHEUMATOID ARTHRITIS;
TREATMENT INDICATION;
TREATMENT OUTCOME;
VASCULITIS;
AGED;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DRUG THERAPY, COMBINATION;
HUMANS;
MALE;
METHOTREXATE;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
VASCULITIS;
|
EID: 32144438288
PISSN: 0315162X
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
Times cited : (9)
|
References (7)
|